Prescient Therapeutics’ First-in-Class Cancer Drug Approaching a Pivotal Moment
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b...
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b...
Prescient Therapeutics (ASX:PTX) is at the forefront of this approach with PTX-100, a small molecule which...
Prescient Therapeutics Ltd (ASX:PTX) is seeking to raise up to $7 million through a Share Purchase...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO, James McDonnell, held an investor briefing...
Prescient Therapeutics Limited has reported significant advancements in its clinical trial for PTX-100, with patient...
Prescient Therapeutics anchors biotech penny watchlists as its OmniCAR cell therapy platform draws steady attention,...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO, James McDonnell, held an investor briefing...
Prescient Therapeutics: Explainer with CEO James McDonnell CEO James McDonnell, recorded a short video explaining...
Experienced oncology drug development executive Dr Rosalind Wilson is joining Prescient Therapeutics Ltd (ASX:PTX) as chief medical...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.